Media stories about Aquinox Pharmaceuticals (NASDAQ:AQXP) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a news impact score of 0.07 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.9334679755062 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several analysts have recently weighed in on the stock. ValuEngine upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Canaccord Genuity set a $22.00 price target on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, BidaskClub cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Aquinox Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $22.25.
Aquinox Pharmaceuticals (NASDAQ AQXP) traded down 4.3244% during trading on Friday, hitting $13.5381. 40,572 shares of the stock were exchanged. Aquinox Pharmaceuticals has a one year low of $9.83 and a one year high of $19.97. The stock’s 50 day moving average is $14.33 and its 200-day moving average is $14.80. The company’s market cap is $317.66 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.59). On average, equities research analysts expect that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Aquinox Pharmaceuticals (NASDAQ:AQXP) Receiving Somewhat Favorable Press Coverage, Analysis Shows” was first published by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/aquinox-pharmaceuticals-aqxp-receives-media-impact-score-of-0-07/1565216.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.